Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Preventing Opioid Overdose at Reentry through Jail- and Community-based Programs
January 14, 20202:00-3:30pm ET
Michele Worobiec, JD, CCMBruce W. Herdman, PhD, MBA
Hosted by SAMHSA’s GAINS Center
2
Welcome and Housekeeping
Dan Abreu, MS, CRC, LMHCSenior Project AssociateCriminal Justice Division
Policy Research Associates, Inc.
The views, opinions, and content expressed in this presentation and discussion do not necessarily reflect the
views, opinions, or policies of the Center for Mental Health Services (CMHS), the Center for Substance Abuse
Treatment (CSAT), the Substance Abuse and Mental Health Services Administration (SAMHSA), or the U.S. Department
of Health and Human Services (DHHS).
3
Disclaimer
4
Welcome Dan Abreu, MS, CRC, LMHCSenior Research Associate, Policy Research Associates, Inc.
Opening Remarks Jon BergSenior Public Health Advisor, SAMHSA
Presentation Michele Worobiec, JD, CCMVice President and Chief CounselTreatment Alternatives for Safe Communities (TASC)
Bruce W. Herdman, PhD, MBAChief of Medical OperationsPhiladelphia Department of Prisons
QuestionsClosing Remarks
Dan Abreu, MS, CRC, LMHCSenior Research Associate, Policy Research Associates, Inc.
Agenda
5
Opening Remarks
Jon BergSenior Public Health Advisor
Center for Substance Abuse TreatmentSAMHSA
6
Introducing Today’s Presenters: Michele Selig Worobiec, JD, CCM
• Is Vice President and Chief Counsel for Treatment Alternatives for Safe Communities (TASC).
• Provides executive leadership in corporate governance, legal risk management, policy and legislative initiatives, justice system relations, and national and international consulting.
• Served previously on the bench in Ohio for seven years, presiding over criminal and civil cases as well as the drug, mental health, and veterans courts.
• Was previous policy counsel for the Supreme Court of Ohio. • Holds a number of leadership positions, including serving as a board
member of the National Alliance for Model State Drug Laws (NAMSDL).
Introducing Today’s Presenters: Bruce W. Herdman, PhD, MBA
• Is Chief of Medical Operations at Philadelphia Department of Prisons, Pennsylvania.
• Has held numerous health care administration positions in Philadelphia, including Executive Director of the Philadelphia Mayor's Commission on Health, Senior Vice President for Psychiatric Services at Pennsylvania Hospital, Vice President for Risk Arrangements and Ancillary Services at Independence Blue Cross (PA), and Senior Vice President of Provider Network Management at Keystone Mercy Health Plan (PA).
• Is responsible for the delivery and quality of the medical, behavioral health, and dental services provided to over 25,000 incarcerated individuals annually at the prison and in the community.
7
Preventing Opioid Overdose Death at Reentry: Framework
January 14, 2020
Michele Worobiec, JD, CCMVice President and Chief Counsel
Treatment Alternatives for Safe Communities (TASC)
9
Framework: The Five Critical Activities
1. Minimize drug-enabling housing.2. Minimize overdose deaths within two weeks of release.3. Maximize rapid access to drug treatment.4. Minimize drug market activity.5. Minimize overdose deaths beyond two weeks; maximize
ongoing recovery.
10
Benefits of the Five Critical Activities
∙ Community safety
∙ Lives saved∙ Successful
recovery
The five critical
activities
Crime & drug use reduction
• Activities may benefit many, but the framework is focused on people who are justice-involved and at highest risk of overdose (OD), including:
Those with a known history of opioid use including OD.
Those who have received opioid overdose reversal with naloxone (Narcan®) in the past.
11
Target Population for the Framework
• Potential sources of individualized information:
Medical records (jail or other provider, if released)
Client (self-report, urinalysis)
Arrest and conviction record
Prescription Drug Monitoring Program (PDMP)
12
Target Population for the Framework (Continued)
13
Minimize Drug-enabling Housing.
Critical Activity 1
14
Activity 1: Minimize Drug-Enabling Housing.
Why do this?• People, places, and things…
• Can be found in the home.• Are where the person is likely to spend much of their time.
• Saliency of drug experiences makes “it” real even if drugs and paraphernalia are not present.
• Person needs to avoid triggering environments.• Others in home might be in recovery or actively using drugs.
15
Critical Activity 2
Minimize Overdose Death within Two Weeks of Release.
16
Activity 2: Minimize Overdose Deaths.
Why do this?• There is a 12x increase in overdose (OD) deaths upon
release from any residential setting where substance use has not been possible. This includes jail, residential treatment facilities, and
other restricted settings.• Risk for OD death is higher than all other heightened risks
at reentry.
17
Activity 2: Minimize Overdose Deaths (Continued).
Why do this?• Upon release, people may quickly return to pre-incarceration
drug dosages.• Tolerance for higher dosages no longer exists.• This is especially acute for opioids. Impact of fentanyl
18
Critical Activity 3
Maximize Rapid Access to Drug Treatment.
19
Activity 3: Maximize Rapid Access to Drug Treatment.
Why do this?• The path to reducing drug use requires rapid access to
and retention in the appropriate level of treatment, including when someone returns to using substances.
• Inclusion criteria should not require subjective items such as motivation for change or readiness for treatment.
• Rapid access provides opportunity to address co-occurring diagnoses (often mental health).
• Reduced drug use reduces crime.
20
Critical Activity 4
Minimize Drug Market Activity.
21
Activity 4: Minimize Drug Market Activity.
Why do this?• Drug Market activity… Disrupts the community/neighborhood. Creates fear in the public. Brings street gang activity and heightened police presence. Instigates crime, especially violent crime: shootings,
battery, and theft. Provides ready access to drugs.
(Resource: National Network for Safe Communities Drug Market Intervention)
22
Critical Activity 5
Minimize Overdose Deaths Beyond Two Weeks.
23
Activity 5: Minimize Overdose Deaths Beyond Two Weeks.
Why do this?• There is continued high risk of OD beyond two weeks
(risk reduces with treatment).• Treatment engagement and retention are key. • Substance use disorders may be chronic and recovery is
a lifelong process.• Relapse ≠ failure and is often part of the process.• Recovery supports are needed for durable recovery.
Critical Activities needed for those who are at highest risk of opioid overdose death:
• Housing that does not support drug use• Tight wrap around and handoffs that start immediately and last
for at least two weeks post release• Rapid access to all needed drug treatment• Minimized drug market activity• Ongoing monitoring and recovery support beyond those first
two weeks
24
Framework Summary
Medication-assisted Treatment for Justice-involved People: The Role of the Jail
January 14, 2020
Bruce W. Herdman, PhD, MBAChief of Medical Operations
Philadelphia Department of Prisons
Philadelphia Department of Prisons (PDP): Charges
(Source: Philadelphia Department of Prisons; April 2019 snapshot)
26
Who We Serve
People in the Jail: Characteristics #/%
African American 66%
Hispanic 19%
Caucasian 12%
Other 3%
Average age 34
Average grade completed 11
Average reading level 5th Grade
Experiencing homelessness 30%
From medically underserved areas (“MUAs”) 80%
Percentage with health insurance (on release) 92%
Average # of incarcerations 6.5 – 7.9
Average # of aliases 2.6
27
(Source: Philadelphia Department of Prisons; April 2019 snapshot)
Days to Release
2%
13%20%
25% 28% 31% 34% 35% 36% 37% 38% 39% 40% 41%
57%
67%74%
0%
10%
20%
30%
40%
50%
60%
70%
80%
1 Da
y or
Les
s
2 Da
ys o
r Les
s
3 Da
ys o
r Les
s
4 Da
ys o
r Les
s
5 Da
ys o
r Les
s
6 Da
ys o
r Les
s
7 Da
ys o
r Les
s
8 Da
ys o
r Les
s
9 Da
ys o
r Les
s
10 D
ays o
r Les
s
11 D
ays o
r Les
s
12 D
ays o
r Les
s
13 D
ays o
r Les
s
14 D
ays o
r Les
s
30 D
ays o
r Les
s
60 D
ays o
r Les
s
90 D
ays o
r Les
s
28 (Source: Philadelphia Department of Prisons; as of October 2019)
The Illness Opportunity
Serious Mental Illness 16%Behavioral Health Caseload 37%HIV 2.5%Chlamydia 3.6%Gonorrhea 0.9%Syphilis 2.2%Diabetes 5%Hypertension 12%Seizure Disorders 6%Substance Use Disorder (SUD) 75%+Hepatitis C 18% / 8.2%
29
(Source: Philadelphia Department of Prisons; as of October 2019)
Drugs “On board” at Admission (2013 Data)
• 41% of all citizens incarcerated in PDP reported drug use.
• 74% of all citizens incarcerated in PDP tested positive for use at admission. 59% marijuana 22% cocaine 21% benzodiazepines 14% opiates 8% Phencyclidine (PCP) 4% amphetamines 3% methadone 3% barbiturate
30
Resources
Services Delivery
Cardiology, Dentistry, Dialysis, OB/GYN, Optometry,Physical Therapy, Podiatry, Primary Care, Psychiatry, Routine Chronic Care, Wound Care
On Campus
All Other Specialists Off Campus
Laboratory Services 2-day turnaround or “STAT”
Pharmacy Same day or “Stock Meds”
X-ray Digital
Facility Staff
Corizon 250 FTEs
Centurion 119 FTEs
AmeriHealth All Hospitals / 90% of all physicians
31
Pennsylvania: The Opioid Epidemic
2014: Pennsylvania Physician General standing order for naloxone
2015: 702 drug overdose deaths in Philadelphia
2016: 907 drug overdose deaths in Philadelphia
2017: 1172 drug overdose deaths in Philadelphia
2018: 939 drug overdose deaths in Philadelphia
2019: 1100+ drug overdose deaths in Philadelphia
32
Pennsylvania Department of Prisons (PDP) SUD Programming
1993 2004 2017 2018 2019 2020OPTIONS treatment program (Opportunities for Prevention & Treatment Interventions for Offenders Needing Support)
Methadone maintenance by community treatment provider (CTP)
Public Service Announcement (PSA) Education of Inmates, Visitors & Officers
Nasal naloxone (Narcan) kit distribution (N=5,500 Kits)
Buprenorphine induction women’s jail pilot: 5-day prescription for buprenorphine at discharge
Release with Care Program
Buprenorphine induction: Women & Men; No prescriptions
Naltrexone (Vivitrol)
Buprenorphine-naloxone (Suboxone) induction: Women & Men; 5-day prescription for buprenorphine-naloxone on Release
CTP visits on campus
Buprenorphine induction: Women & Men; five days of Suboxone pills on release
Referrals and discharge summaries to Community Treatment Programs
Enrollment in Medical Assistance
Methadone induction
Buprenorphine extended-release (Sublocade)
Current medical assistance enrollment (90%)
Peer Navigation
Coordination with Department of Behavioral Health
Rigorous Program Evaluation
33
• Release with Care staff meet patients within the 3rd business day after release. Patient and staff select a community medication-assisted treatment (MAT)
Center of Excellence. A referral is sent to that community MAT Center of Excellence. Post release appointments are made for sentenced patients. A discharge summary is sent to the relevant Center of Excellence on release.
• Patients on buprenorphine-naloxone (Suboxone) receive at least 5-days of medication (buprenorphine-naloxone pills) on release to the street.
• Release with Care staff complete and submit medical assistance (MA) applications the first day after release (MA is effective the day of release).
Preliminary results: 42% of women in the buprenorphine-naloxone program released with a prescription for buprenorphine-naloxone received substance use or behavioral health care or both within 30 days of release. 34
Current Discharge Planning/Execution
• Offer methadone induction (now only offered to pregnant patients with opioid use disorder (OUD)).
• Offer Sublocade at release.• Expand peer navigation services before/after release.• Coordinate MAT releases with Department of Behavioral Health.• Enhance cognitive behavioral therapy services.• Complete rigorous program evaluation.• Coordination with Probation and Parole.
35
2020 Program Plans
Issues
• Waiver Limitations • Drug Enforcement Administration (DEA) Oversight • Diversion • Cost • Stigma• HIPAA• Housing
36
Preventing Opioid Overdose Death at Reentry: Corrections Transition Program
January 14, 2020
Michele Worobiec, JD, CCMVice President and Chief Counsel
Treatment Alternatives for Safe Communities (TASC)
• CTP is located at Sheridan Correctional Center in Chicago, IL.
• Residents engage in substance use treatment, vocational and/or educational training, employment readiness programming, and specialized reentry case management.
• As a condition of parole, participants agree to continue community substance use treatment (or aftercare) and case management for at least 90 days.
38
Corrections Transition Program (CTP)
• TASC provides specialized case management to assess needs, link participants to planned services, engage clients and monitor their progress, and respond to additional needs that emerge.
• Grant funding supports initiating medication-assisted treatment (MAT) prior to release.
• Parole agents attend to program compliance and community safety issues.
39
Corrections Transition Program (Continued)
People are eligible for the program who:• Voluntarily choose to participate. • Are in need of substance use treatment. • Have between 9-36 months left to serve in prison. • Are eligible for placement in a medium security prison. • Have no disqualifying offenses.• Do not suffer from severe mental illness that would
interfere with their participation.
40
Entry Into the Program
Admissions Process:• Department of Corrections screens residents for initial
eligibility. • Clinical substance use assessments determine the need
for treatment.
41
Entry Into the Program (Continued)
Pre-Release Case Management Services• Strength and needs-based assessment for treatment,
housing, employment, other• Discharge planning• Post-release placement in community services• Health care coverage navigation
42
TASC’s Specialized Case Management
Post-Release Case Management Services• Ensure engagement in substance use treatment and
other needed services upon release.• Monitor progress through client engagement and
communication with providers.• Identify and respond to additional needs that emerge. • Offer high intensity services to address risk for
overdose death and other urgent needs.
43
TASC’s Specialized Case Management (Continued)
• Improved justice goals 21 percent lower risk of re-arrest for a new offense (33
percent lower risk if the participant was at Sheridan Correctional Center for at least nine months)
44 percent lower risk of re-incarceration
44
Key Research Findings: Program Benefits
• Improved well being More successful in obtaining and keeping a job Improved levels of psychological and social functioning and
reduced criminal thinking patterns
• Improved rate of aftercare admissions and completion Achieved through coordination of pre-release planning,
community-based partnerships, and transformation of the parole model
More successful in overcoming barriers to effective re-entry
45
Key Research Findings: Program Benefits (Continued)
Trends among participants who experienced recidivism reinforce the framework’s critical activities.
Housing• Those who returned to their original neighborhood
returned to substance use sooner. • Those living in neighborhoods that were perceived as
unsafe and/or where drug dealing was common returned to substance use sooner.
46
Factors Related to Recidivism and Substance Use
• Activities Unemployed participants engaged in criminal activity sooner. Those who spent time with people engaged in substance use
and/or criminal activity returned to substance use sooner. Those with gang involvement engaged in criminal activity and
returned to substance use sooner.
• Treatment Those who did not complete aftercare engaged in criminal
activity and returned to substance use sooner.
47
Factors Related to Recidivism and Substance Use
The Corrections Transition Program addresses the key needs for those at highest risk of opioid overdose death:• Housing that does not support drug use is secured prior to
release.• Tight wraparound and handoffs start immediately and last for
at least two weeks post-release for a seamless transition from pre- to post-release case managers.
48
Back to the Framework
• Rapid access to all needed drug treatment continues with the appropriate levels of care in the community.
• Minimizing drug market activity factors into service planning, partner relationships, and advocacy.
• Ongoing, specialized case management goes beyond the first two weeks.
49
Back to the Framework (Continued)
50
Additional Resources
https://store.samhsa.gov/product/Use-of-Medication-Assisted-Treatment-for-Opioid-
Use-Disorder-in-Criminal-Justice-Settings/PEP19-MATUSECJS
https://store.samhsa.gov/product/Opioid-Overdose-Prevention-Toolkit/SMA18-
4742
Substance Abuse and Mental Health Services AdministrationSAMHSA’s mission is to reduce the impact of substance abuse
and mental illness on America’s communities.www.samhsa.gov
1-877-SAMHSA-7 (1-877-726-4727) ● 1-800-487-4889 (TDD)
GAINS Center for Behavioral Health and Justice TransformationThe GAINS Center focuses on expanding access to services for people with
mental and/or substance use disorders who come into contact with the justice system.
https://www.samhsa.gov/gains-center1-800-311-4246
Thank You
51